文献速递类风湿关节炎

COBRA-light与COBRA方案治疗早期类风湿关节炎4年疗效与安全性相似

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

COBRA-light试验将162例新发RA患者随机分配至COBRA-light(泼尼松+MTX)或COBRA(泼尼松+MTX+SSZ)治疗1年,4年后149例(92%)参与扩展研究。初始COBRA-light与COBRA治疗在4年随访期间对疾病活动度、身体功能、影像学结局和Boolean缓解的影响相似,两组生存率和主要合并症也相似。

要点

  • COBRA-light与COBRA方案4年疗效相似,包括疾病活动度、功能和影像学结局。
  • 两组生存率和主要合并症相似,但检测差异的把握度有限。
  • 除方案规定的泼尼松、MTX和SSZ差异外,其他DMARD及激素使用相似。

核心结论

  • 早期RA患者初始接受COBRA-light或COBRA治疗,4年随访期间疗效和安全性结局相似。

研究设计与样本

  • COBRA-light试验随机分配162例新发RA患者至COBRA-light(泼尼松+MTX)或COBRA(泼尼松+MTX+SSZ)治疗1年,4年后149例(92%)参与扩展研究。

主要发现

  • 4年随访期间,初始COBRA-light与COBRA治疗对疾病活动度、身体功能、影像学结局和Boolean缓解的影响相似。
  • 两组生存率和主要合并症相似,但检测差异的把握度有限。
  • 除方案规定的泼尼松、MTX和SSZ使用差异外,其他合成及生物DMARD和关节内/肌内糖皮质激素注射的使用在两组间相似。

临床怎么用

  • 对于早期RA患者,COBRA-light可作为与COBRA方案疗效和安全性相似的初始治疗选择。

局限性

  • 检测两组间生存率和主要合并症差异的把握度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of initial COBRA-light vs COBRA therapy in RA patients after a 4-year follow-up period. METHODS: In the COBRA-light trial, 162 consecutive patients with recent-onset RA were randomized to either COBRA-light (prednisolone and MTX) or COBRA therapy (prednisolone, MTX and SSZ) for 1 year. After 1 year, treatment was continued without protocol, and adjusted by the treating physician according to clinical judgement, preferably with a treat-to-target strategy. Four years after trial initiation, all patients were invited to participate in the COBRA-light extension study, in which patients were interviewed and physically examined, patient reported outcomes were assessed, radiographs were made and clinical records were examined for comorbidities and medication use. RESULTS: In the extension study, 149 out of 162 (92%) original trial patients participated: 72 COBRA-light and 77 COBRA patients. Initial COBRA-light and COBRA therapy showed similar effect on disease activity, physical functioning, radiological outcome and Boolean remission over the 4-year follow-up period. In addition, both treatment groups showed similar survival and major comorbidities, although the power to detect differences was limited. Besides protocolled differences in prednisolone, MTX and SSZ use, the use of other synthetic and biologic DMARDs and intra-articular and intramuscular glucocorticoid injections was similar in both treatment groups over the 4-year period. CONCLUSION: Early RA patients initially treated with COBRA-light or COBRA therapy had similar efficacy and safety outcomes over a 4-year follow-up period.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Konijn NPC, van Tuyl LHD, Boers M, et al. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. Rheumatology (Oxford). 2017. PMID: 28859326. doi:10.1093/rheumatology/kex223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。